| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10908641 | Leukemia Research | 2015 | 23 Pages |
Abstract
- Imatinib resistance leads to MRP1-5, ABCA2 and ABCG2 transporters overexpression.
- Celecoxib and imatinib co-treatment inhibited the expression of ABC transporters.
- Ras-Raf-Mek-Erk-CREB and GSK-3β-β-catenin-TCF4-LEF1 pathways are inhibited.
- Celecoxib sensitizes resistant cells to imatinib by inhibiting ABC transporters.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Gangappa Dharmapuri, Ravinder Doneti, Gundala Harold Philip, Arunasree M. Kalle,